• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Meril’s bioresorbable, drug-eluting vascular scaffold

February 22, 2017 By Sarah Faulkner

Meril's bioresorbable, drug-eluting vascular scaffoldMeril Life Sciences has developed a drug-eluting, bioresorbable vascular scaffold that the body can slowly degrade and wash away.

The company’s MeRes100 is made of biodegradable polymers, PLLA and PDLLA. Sirolimus, a commonly-used immunosuppressant found in drug eluting stents, is embedded in the scaffold’s coating.

The company designed the struts of the device to be just 100 μm thick, while still providing the strength needed to maintain an open lumen.

In October last year, Meril touted 6-month data from the 1st-in-man study of the MeRes100 scaffold in patients with coronary artery disease at the annual Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.

The data showed that at 6 months, the scaffold was safe and effective with no major adverse cardiac events.

The trial enrolled 108 patients at 16 sites across India from May 2015 to April 2016. Researchers reported no major adverse cardiac events up to the 6-month follow-up. Quantitative coronary analysis data showed favorable in-scaffold late lumen loss, according to Meril.

“The innovative design of the MeRes100 scaffold developed in India addresses some of the limitations of currently available [bioresorbable scaffolds],” chairman of the Fortis Escorts Heart Institute Ashok Seth said in prepared remarks. “The MeRes-1 first-in-man study demonstrates that this new generation thinner-strut sirolimus-eluting BRS is safe and effective at 6 months. These encouraging results provide the basis for further studies using a wider range of length and sizes in more complex and larger patient population moving to a randomized pivotal trial against the second-generation metallic drug-eluting stents by mid 2017.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Meril

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS